A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: April 12, 2010
Last updated: March 3, 2014
Last verified: March 2014

This open-label study will assess the pharmacokinetics, efficacy and safety of RO5185426 administered as 240mg tablets in previously treated patients with metastatic melanoma. Patients will be randomized to receive one of four dose-levels of RO5185426 [RG7204; PLEXXIKON; PLX4032] orally twice daily on days 1 to 15 (morning dose). Starting on day 22, treatment with RO5185426 may be resumed at a dose of 960 mg twice daily and continued until disease progression. Target sample size is <100 patients.

Condition Intervention Phase
Malignant Melanoma
Drug: RO5185426
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Randomized, Open-label, Multi-center, Multiple Dose Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO5185426 Administered as 240 mg Tablets to Previously Treated BRAF V600E Positive Metastatic Melanoma Patients

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Pharmacokinetics: RO5185426 plasma concentration [ Time Frame: multiple sampling days 1, 2, 9, 11, 15, 16 and 18; and on day 1 cycles 1-8 and every other cycle starting cycle 9 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and tolerability: Incidence of adverse events (AEs) [ Time Frame: throughout study ] [ Designated as safety issue: No ]
  • Safety and tolerability: Assessment of routine laboratory values [ Time Frame: laboratory assessments every 3 weeks ] [ Designated as safety issue: No ]
  • Efficacy: Best overall response (OR) [ Time Frame: tumor assessments every 2 cycles ] [ Designated as safety issue: No ]
  • Efficacy: Overall survival (OS) [ Time Frame: event driven, assessed at study completion ] [ Designated as safety issue: No ]

Enrollment: 52
Study Start Date: May 2010
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: RO5185426
960 mg orally twice daily, from day 22 onward
Drug: RO5185426
dosage a) orally twice daily, days 1-15 (morning dose)
Experimental: 2 Drug: RO5185426
dosage b) orally twice daily, days 1-15 (morning dose)
Drug: RO5185426
960 mg orally twice daily, from day 22 onward
Experimental: 3 Drug: RO5185426
dosage c) orally twice daily, days 1-15 (morning dose)
Drug: RO5185426
960 mg orally twice daily, from day 22 onward
Experimental: 4 Drug: RO5185426
dosage d) orally twice daily, days 1-15 (morning dose)
Drug: RO5185426
960 mg orally twice daily, from day 22 onward


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, >/=18 years of age
  • histologically confirmed metastatic melanoma, stage IIIc or IV (AJCC)
  • failure of at least one prior standard of care regimen
  • positive for BRAF V600E mutation (by Roche CoDx BRAF mutation assay)
  • ECOG performance status 0 or 1
  • adequate hematologic, renal and liver function

Exclusion Criteria:

  • active CNS lesions on CT/MRI within 28 days prior to enrollment
  • history of spinal cord compression o carcinomatous meningitis
  • anticipated or ongoing anti-cancer therapies other than those administered in this study
  • previous treatment with BRAF inhibitor (sorafenib allowed) or MEK inhibitor
  • severe cardiovascular disease within 6 months prior to study
  • previous malignancy within the past 5 years except for basal or squamous cell carcinoma of the skin, melanoma in-situ and carcinoma in-situ of the cervix
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01107418

United States, California
La Jolla, California, United States, 92093
San Francisco, California, United States, 94115
Stanford, California, United States, 94305
United States, Connecticut
New Haven, Connecticut, United States, 06510-3289
United States, Illinois
Chicago, Illinois, United States, 60637
Park Ridge, Illinois, United States, 60068
United States, Iowa
Sioux City, Iowa, United States, 51101
United States, Nebraska
Omaha, Nebraska, United States, 68114
United States, Ohio
Columbus, Ohio, United States, 43219
United States, Rhode Island
East Providence, Rhode Island, United States, 02915
United States, Virginia
Charlottesville, Virginia, United States, 22908
Australia, South Australia
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Melbourne, Victoria, Australia, 3181
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided by Hoffmann-La Roche

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01107418     History of Changes
Other Study ID Numbers: NP25163
Study First Received: April 12, 2010
Last Updated: March 3, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas

ClinicalTrials.gov processed this record on July 29, 2015